Vimarsana
Biggest News Aggregation in the World

Page 2 - Yi Lin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Yi Lin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Yi Lin Today - Breaking & Trending Today

NASA's Sulphur Selenium Battery: Electric Aircraft's Future? - Vimarsana News

NASA's Sulphur Selenium Battery: Electric Aircraft's Future?

NASA's SABERS initiative reveals a new solid-state battery using sulfur and selenium, presenting an efficient alternative for modern aviation.

Naga 3 pushed back till Sept 2029 - Vimarsana News

Naga 3 pushed back till Sept 2029

Hong Kong-listed casino operator and developer NagaCorp Ltd, known for its flagship NagaWorld integrated resort in Phnom Penh, on June 4 announced that it has moved the $3.5 billion Naga 3 project’s planned completion date from September 30, 2025 to exactly four years later, in a bid to cut capital expenditure (capex) amid global economic concerns.

2seventy bio, Inc.: 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 - Vimarsana News

2seventy bio, Inc.: 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 - Vimarsana News

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from... | May 11, 2023

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023 - Vimarsana News

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of... | May 11, 2023